FDA Seeks Comment on New Draft Guidance for Biosimilars: “Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product” Read more
Physician Payments Sunshine Act: No Word Yet From CMS on Phase 2, Which Will “Start in May” Read more